Monday, June 27, 2022 11:36:36 AM
BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, presented in vivo data at the 2022 ECM Pharmacology Congress in Copenhagen that demonstrated NC410 remodels tumor ECM, enhances immune cell infiltration, alleviates immunosuppression, and reduces tumor growth in a humanized mouse tumor model.
The presentation, titled “NC410 (LAIR-2-Fc Fusion Protein): Overcoming Clinical Limitations to Immunotherapy Through Targeting and Remodeling Tumor ECM,” details a study of NC410 that showed by binding collagen in the tumor microenvironment, NC410 was able to remodel the architecture of the tumor ECM and restore normal immune function. ECM remodeling was associated with an enhancement of immune cell infiltration, increased activation of CD8+ T cells, repolarization of suppressive macrophages and a reduction in tumor growth.
“Collagen in the tumor ECM is a potent immunosuppressor, creates a physical barrier to immune cell penetration and is correlated with resistance to currently available immunotherapies. Our data show that NC410 has a unique and novel mechanism to overcome collagen-mediated resistance by remodeling tumor ECM architecture,” said Sol Langermann, Ph.D., NextCure’s chief scientific officer. “NC410 has repeatedly demonstrated the ability to bind to collagen in tumor ECM and remodel the architecture, which enables immune cell infiltration and activation and allows T cells to effectively fight cancer. We look forward to continuing the evaluation of NC410 in our ongoing Phase 1/2 study and investigating biomarkers from patient samples for evidence of ECM remodeling and immune cell activity.”
Highlights of the data presented include:
NC410 binds to collagen-rich areas where LAIR-1+ immune cells are localized.
NC410 promotes ECM remodeling and reduces tumor growth in humanized mouse tumor models.
NC410 synergizes with PD-L1 targeting and provides long-term tumor-specific protection not achieved with individual compounds.
NC410 is currently being evaluated in a Phase 1/2 study in subjects with advanced or metastatic solid tumors. An update to the Phase 1 portion of the trial will be provided in the second half of 2022.
About NC410
NC410 is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells, a type of antigen presenting cell. In preclinical research, it has been shown that LAIR-1 inhibits T cell function and myeloid activity. In preclinical studies, NC410 blocks the negative effects of LAIR-1 and promotes T cell function and myeloid cell activity. NextCure believes NC410 has the potential to treat multiple cancer types.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com
Cautionary Statement Regarding Forward-Looking Statements
Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives, and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent NXTC News
- NextCure Provides Business Update and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024 • GlobeNewswire Inc. • 04/24/2024 08:05:00 PM
- NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 • GlobeNewswire Inc. • 04/08/2024 11:00:00 AM
- NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board • GlobeNewswire Inc. • 04/04/2024 11:05:00 AM
- NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- NextCure Provides Business Update and Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/21/2024 12:55:00 PM
- NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances • GlobeNewswire Inc. • 03/05/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 09:45:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 09:45:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 09:44:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 09:44:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 09:43:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 09:43:21 PM
- NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders • GlobeNewswire Inc. • 01/18/2024 09:05:00 PM
- NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury • GlobeNewswire Inc. • 12/21/2023 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 12:15:59 PM
- NextCure Provides Year-End Clinical Pipeline Updates • GlobeNewswire Inc. • 12/14/2023 11:45:00 AM
- NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/20/2023 12:00:00 PM
- NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML • GlobeNewswire Inc. • 11/15/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 08:20:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 08:10:28 PM
- NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/02/2023 08:05:00 PM
- Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI) • GlobeNewswire Inc. • 10/17/2023 12:05:00 PM
- NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease • GlobeNewswire Inc. • 09/26/2023 08:05:00 PM
- A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC • GlobeNewswire Inc. • 09/12/2023 12:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM